Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.30441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP/myeloid mixed-phenotype acute leukemia: a case report.
Front Oncol
August 2025
Department Hematopathology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
Background: Mixed-phenotype acute leukemia (MPAL) is a rare acute leukemia for which data are currently not available to guide therapy. It has a poor outcome, particularly in elderly patients.
Case Presentation: We report the successful use of venetoclax/azacitidine as treatment for a treatment-naive elderly patient with early T-cell precursor (ETP)/myeloid MPAL.
B/T mixed phenotype acute leukemia revealing immunophenotypic lineage-genotype associations and frequent myelodysplasia-related cytogenetic/gene abnormalities: implication for diagnosis and treatment.
Ann Diagn Pathol
August 2025
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address:
B/T mixed-phenotype acute leukemia (MPAL) is a rare subtype of leukemia with diagnostic and therapeutic challenges due to its rarity, genomic diversity, and evolving diagnostic criteria. We report six cases of B/T MPAL with clinicopathological and genomic characterization. Most cases (5/6) demonstrated immunophenotypic/lineage-genotype-associations, i.
View Article and Find Full Text PDFPhiladelphia chromosome-positive mixed-phenotype acute leukemia: a case report and literature review.
Front Oncol
July 2025
Department of Hematology, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Introduction: Mixed-phenotype acute leukemia (MPAL) is a rare type of acute leukemia with an incidence of less than 5% and Philadelphia chromosome-positive (Ph+) represents a distinct subtype.
Case Description: An 18-year-old female complained of recurrent fever with fatigue and chills for one month, and a week of growing lymphadenectasis. Bone marrow examination revealed two distinct populations of blast cells and the presence of fusion gene, leading to a diagnosis of Ph+ MPAL.
PAX5 as a diagnostic tool in unconventional acute leukemia: Establishing immunohistochemical evidence of B-cell lineage.
Hum Pathol
September 2025
Yale University Department of Pathology, New Haven, CT, USA. Electronic address:
Acute leukemia lineage assignment is critical for clinical management. When CD19 expression is dim by flow cytometry, it becomes challenging to meet criteria for B-lymphoblastic leukemia/lymphoma (B-ALL) or B-lineage in mixed phenotype. While many B-lineage specific markers are available by immunohistochemistry (IHC), they have not been systematically validated.
View Article and Find Full Text PDFThe Emergence of Subclones Following Initial Chemotherapy in Mixed Phenotype Acute Leukemia.
Cureus
July 2025
Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Osaka, JPN.
Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemias, and it is characterized by the immunophenotypic expression of multiple hematopoietic lineages and the potential for lineage switching post-treatment. Diagnosing MPAL can be challenging, particularly in cases with small immunophenotypically distinct subclones or subpopulations exhibiting weak antigen expression. We present two cases of MPAL where subclones or lineage switches emerged following initial treatment.
View Article and Find Full Text PDF